Market Place
Sourcing Support
Venus Remedies gets GMP approval for pre-filled syringe facility
05 Nov 2024 //
ECONOMICTIMES
Venus Remedies got Marketing Authorisations For Oncology Drugs
01 Oct 2024 //
INDPHARMAPOST
Venus Remedies Get Market Authorisations For Two Cancer Drugs
30 Sep 2024 //
ECONOMICTIMES
Venus Remedies Gets Approvals For Oncology Drugs In Two Countries
30 Sep 2024 //
PHARMABIZ
Venus Remedies Clinches WHO-Backed PAHO Tender
25 Jun 2024 //
INDIANPHARMAPOST
Venus Remedies clinches dual tender from globally acclaimed UNICEF & PAHO
20 Jun 2024 //
PHARMABIZ
Harness data to unleash power of Indian pharma industry
02 Apr 2024 //
EXPRESS PHARMA
Venus Remedies receives Rs. 2.50 crore under PLI scheme
01 Apr 2024 //
INDINPHARMAPOST
Venus Remedies secures regulatory approvals for three key onco drugs Ukraine
20 Mar 2024 //
INDIANPHARMAPOST
Venus Remedies gets marketing authorisations for three cancer drugs from Ukraine
18 Mar 2024 //
ECONOMIC TIMES
Venus Remedies gets huge global acclaim with UNICEF GMP approval
12 Mar 2024 //
INDIAN PHARMA POST
Venus Remedies secures marketing approval for two oncology drugs
30 Dec 2023 //
INDIAN PHARMA POST
Venus Remedies expands presence with marketing authorisation for enoxaparin
13 Dec 2023 //
INDIAN PHARMA POST
Venus Remedies granted market authorizations in Saudi Arabia and Philippines
02 Dec 2023 //
INDIAN PHARMA POST
Venus Remedies earns REO Certification from CII for second consecutive year
26 Oct 2023 //
INDIAN PHARMA POST
Venus gets marketing approval for six chemotherapy drugs from Philippines
16 Oct 2023 //
ECONOMIC TIMES
Venus Remedies expands reach with the launch of Elores in Ecuador
14 Oct 2023 //
INDIAN PHARMA POST
Venus Remedies gets marketing approval for anticoagulant drug in Saudi Arabia
28 Aug 2023 //
ECONOMIC TIMES
Venus Remedies launches flagship R&D drug Elores in Oman
18 Aug 2023 //
ECONOMIC TIMES
Venus Remedies receives Ukrainian GMP approval for Its parenteral facilities
08 Jun 2023 //
INDIAN PHARMA POST
Venus Remedies gets marketing authorization for Docetaxel
01 Jun 2023 //
ECONOMIC TIMES
DSIR Recognition to Venus Remedies` in-house R&D Unit
16 May 2023 //
ECONOMIC TIMES
Venus Remedies bolsters position in oncology space with marketing approval
09 May 2023 //
BIOSPECTRUM ASIA
Venus Remedies joins India AMR Innovation Hub
06 Mar 2023 //
EXPRESS PHARMA
Venus Remedies gets good manufacturing certification from Saudi drug regulator
27 Feb 2023 //
ECONOMIC TIMES
Venus Remedies wins AmbitionBox Best Places to Work in India Award
15 Sep 2022 //
PHARMABIZ
Venus Remedies registers 9.22 pc growth in sales for FY 2021-22
29 May 2022 //
ET HEALTH
Venus Remedies wins WHO GDP certification for quality services
09 Mar 2022 //
PHARMABIZ
Venus Remedies makes the cut for PLI scheme
14 Dec 2021 //
EXPESSPHARMA
Venus Remedies H1 net profit rises 315% at Rs.38.72 crore
03 Nov 2021 //
PHARMABIZ
Venus Remedies eyes higher export revenue, overseas expansion
05 Oct 2021 //
PHARMABIZ
Venus Remedies eyes higher export revenue, overseas expansion
05 Oct 2021 //
PHARMABIZ
Venus Remedies continues to address unmet medical needs through R&D
14 Sep 2021 //
PHARMABIZ
Venus Remedies Q1 net profit rises 629% at Rs. 14.59 crore.
16 Aug 2021 //
PHARMABIZ
Venus Remedies enters consumer healthcare business
16 Jul 2021 //
PHARMABIZ
Venus Remedies launches consumer healthcare division
15 Jul 2021 //
THE ECONOMIC TIMES
Venus Remedies wins legal battle against French firm for paracetamol patent
17 Jun 2021 //
ECONOMIC TIMES
Venus Remedies wins legal battle against French firm for paracetamol patent
17 Jun 2021 //
BUSINESS-STANDARD
Cipla acquires novel anti-infective Elores
19 Oct 2019 //
BIOSPECTRUM ASIA
